Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. Show more

Location: 12278 Scripps Summit Drive, San Diego, CA, 92131, United States | Website: https://www.fatetherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

130.7M

52 Wk Range

$0.66 - $5.92

Previous Close

$1.14

Open

$1.18

Volume

2,659,810

Day Range

$1.10 - $1.22

Enterprise Value

-28.7M

Cash

240.4M

Avg Qtr Burn

-30.83M

Insider Ownership

1.74%

Institutional Own.

94.13%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
FT825/ONO-8250 Details
Solid tumor/s, Cancer

Phase 1

Data readout

FT819 (CAR-19, TCR-KO) Details
Systemic lupus erythematosus

Phase 1

Data readout

FT819 (CAR-19, TCR-KO) Details
B-cell lymphoma, Solid tumor/s, Cancer, Chronic lymphocytic leukemia

Phase 1

Update

Phase 1

Update

Phase 1

Update

FT596 (CAR19, hnCD16, IL-15RF) + rituximab Details
B-cell lymphoma, B-cell malignancies, Chronic lymphocytic leukemia

Failed

Discontinued

Failed

Discontinued

FT596 (CAR19, hnCD16, IL-15RF) + R-CHOP Details
B-cell lymphoma, B-cell malignancies, Chronic lymphocytic leukemia

Failed

Discontinued

FT516 (NK cells - engineered CD16 FcR) Details
Solid tumor/s, B-cell lymphoma, Diffuse large B cell lymphoma

Failed

Discontinued

FT500 (PD1/PD-L1) Details
Solid tumor/s, Cancer

Failed

Discontinued

ProTmune (CD34+) Details
Acute graft-versus host disease

Failed

Discontinued

Failed

Discontinued